This stock is fighting its way out of the basement! 🥊 News shows a strategic acquisition and a path to profitability, while the RSI is climbing from severely oversold levels. The chart is coiling for a move, and today's pop on big volume is the first real spark. The vibe is shifting from despair to potential. This is a speculative BUY for a turnaround play. #OversoldBounce

Their turnaround is working - hitting positive EBITDA AND making smart acquisitions! 📈 The stock got way ahead of itself in early Oct (RSI over 70!), but this 15% dip to oversold levels looks like a gift. Volume confirms the fear is real, making this a prime BUY-the-news opportunity. #DiagnosingProfits

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, the Netherlands, Belgium, Spain, Poland, Italy, rest of European Union, and internationally. Its novel prostate cancer genomic testing solutions are SelectMDx, a non-invasive urine test; and ConfirmMDx, an epigenetic test, which provide physicians with a clinical pathway to identify clinically prostate cancer while minimizing the use of invasive procedures that are prone to complications. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.

MDxHealth S.A. MDXH: 3.6 USD

Bullish views